305 related articles for article (PubMed ID: 25684563)
1. Role of serum toll-like receptors 2 and 4 in non-alcoholic steatohepatitis and liver fibrosis.
Cengiz M; Ozenirler S; Elbeg S
J Gastroenterol Hepatol; 2015 Jul; 30(7):1190-6. PubMed ID: 25684563
[TBL] [Abstract][Full Text] [Related]
2. A novel model using mean platelet volume and neutrophil to lymphocyte ratio as a marker of nonalcoholic steatohepatitis in NAFLD patients: multicentric study.
Abdel-Razik A; Mousa N; Shabana W; Refaey M; ElMahdy Y; Elhelaly R; Elzehery R; Zalata K; Arafa M; Elbaz S; Hafez M; Awad M
Eur J Gastroenterol Hepatol; 2016 Jan; 28(1):e1-9. PubMed ID: 26469357
[TBL] [Abstract][Full Text] [Related]
3. Comparative diagnostic accuracy of red cell distribution width-to-platelet ratio versus noninvasive fibrosis scores for the diagnosis of liver fibrosis in biopsy-proven nonalcoholic fatty liver disease.
Cengiz M; Ozenirler S
Eur J Gastroenterol Hepatol; 2015 Nov; 27(11):1293-9. PubMed ID: 26302023
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).
Verma S; Jensen D; Hart J; Mohanty SR
Liver Int; 2013 Oct; 33(9):1398-405. PubMed ID: 23763360
[TBL] [Abstract][Full Text] [Related]
5. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis.
Alkhouri N; Johnson C; Adams L; Kitajima S; Tsuruno C; Colpitts TL; Hatcho K; Lawitz E; Lopez R; Feldstein AE
PLoS One; 2018; 13(8):e0202226. PubMed ID: 30161179
[TBL] [Abstract][Full Text] [Related]
6. Increased serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease.
Ozturk O; Colak Y; Senates E; Yilmaz Y; Ulasoglu C; Doganay L; Ozkanli S; Oltulu YM; Coskunpinar E; Tuncer I
World J Gastroenterol; 2015 Jul; 21(26):8096-102. PubMed ID: 26185381
[TBL] [Abstract][Full Text] [Related]
7. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of high sensitivity C-reaction protein in non-insulin dependent diabetes mellitus patients with non-alcoholic fatty liver disease.
Bi Y; Min M; Shen W; Deng P; Du Q; Dong M; Liu Y
Int J Clin Exp Pathol; 2015; 8(7):8494-9. PubMed ID: 26339423
[TBL] [Abstract][Full Text] [Related]
9. Plasma Pentraxin 3 Differentiates Nonalcoholic Steatohepatitis (NASH) from Non-NASH.
Boga S; Koksal AR; Alkim H; Yilmaz Ozguven MB; Bayram M; Ergun M; Sisman G; Tekin Neijmann S; Alkim C
Metab Syndr Relat Disord; 2015 Nov; 13(9):393-9. PubMed ID: 26367098
[TBL] [Abstract][Full Text] [Related]
10. Myeloperoxidase and calprotectin; Any role as non-invasive markers for the prediction of ınflammation and fibrosis in non-alcoholic steatohepatitis?
Bıçakçı E; Demirtaş CÖ; Çelikel Ç; Haklar G; Duman DG
Turk J Gastroenterol; 2020 Oct; 31(10):681-687. PubMed ID: 33169705
[TBL] [Abstract][Full Text] [Related]
11. Can serum pin1 level be regarded as an indicative marker of nonalcoholic steatohepatitis and fibrotic stages?
Cengiz M; Ozenirler S; Yücel AA; Yılmaz G
Digestion; 2014; 90(1):35-41. PubMed ID: 25170559
[TBL] [Abstract][Full Text] [Related]
12. Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population.
Nielsen MJ; Leeming DJ; Goodman Z; Friedman S; Frederiksen P; Rasmussen DGK; Vig P; Seyedkazemi S; Fischer L; Torstenson R; Karsdal MA; Lefebvre E; Sanyal AJ; Ratziu V
J Hepatol; 2021 Dec; 75(6):1292-1300. PubMed ID: 34454994
[TBL] [Abstract][Full Text] [Related]
13. New discriminant score to predict the fibrotic stage of non-alcoholic steatohepatitis in Japan.
Kawamura Y; Ikeda K; Arase Y; Sorin Y; Fukushima T; Kunimoto H; Hosaka T; Kobayashi M; Saitoh S; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Kumada H
Hepatol Int; 2015 Apr; 9(2):269-77. PubMed ID: 25788193
[TBL] [Abstract][Full Text] [Related]
14. Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis.
Chalasani N; Abdelmalek MF; Loomba R; Kowdley KV; McCullough AJ; Dasarathy S; Neuschwander-Tetri BA; Terrault N; Ferguson B; Shringarpure R; Shapiro D; Sanyal AJ
Liver Int; 2019 May; 39(5):924-932. PubMed ID: 30253043
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel noninvasive markers for diagnosing nonalcoholic steatohepatitis and related fibrosis by data mining.
Yoshimura K; Okanoue T; Ebise H; Iwasaki T; Mizuno M; Shima T; Ichihara J; Yamazaki K
Hepatology; 2016 Feb; 63(2):462-73. PubMed ID: 26390046
[TBL] [Abstract][Full Text] [Related]
16. Nonalcoholic steatohepatitis associated with metabolic syndrome: relationship to insulin resistance and liver histology.
Jung KY; Cho SY; Kim HJ; Kim SB; Song IH
J Clin Gastroenterol; 2014; 48(10):883-8. PubMed ID: 24440936
[TBL] [Abstract][Full Text] [Related]
17. Serum vascular cell adhesion molecule-1 predicts significant liver fibrosis in non-alcoholic fatty liver disease.
Lefere S; Van de Velde F; Devisscher L; Bekaert M; Raevens S; Verhelst X; Van Nieuwenhove Y; Praet M; Hoorens A; Van Steenkiste C; Van Vlierberghe H; Lapauw B; Geerts A
Int J Obes (Lond); 2017 Aug; 41(8):1207-1213. PubMed ID: 28461687
[TBL] [Abstract][Full Text] [Related]
18. Serum autotaxin levels are correlated with hepatic fibrosis and ballooning in patients with non-alcoholic fatty liver disease.
Fujimori N; Umemura T; Kimura T; Tanaka N; Sugiura A; Yamazaki T; Joshita S; Komatsu M; Usami Y; Sano K; Igarashi K; Matsumoto A; Tanaka E
World J Gastroenterol; 2018 Mar; 24(11):1239-1249. PubMed ID: 29568204
[TBL] [Abstract][Full Text] [Related]
19. Proteomic screening of plasma identifies potential noninvasive biomarkers associated with significant/advanced fibrosis in patients with nonalcoholic fatty liver disease.
Hou W; Janech MG; Sobolesky PM; Bland AM; Samsuddin S; Alazawi W; Syn WK
Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31860081
[TBL] [Abstract][Full Text] [Related]
20. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.
Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Hultcrantz R; Kechagias S
J Hepatol; 2017 Dec; 67(6):1265-1273. PubMed ID: 28803953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
